Skip to main content
. Author manuscript; available in PMC: 2021 Jul 10.
Published in final edited form as: ACS Infect Dis. 2020 Jun 24;6(7):1976–1997. doi: 10.1021/acsinfecdis.0c00326

Table 3:

Summary of characterization of all three inhibitors against purified NpsA.

Cmpd appKi, (nM) KD (mM) ΔH (kcal/mol) S (kcal/mol) ΔG (kcal/mol) n
5 (5.4 ± 0.8) × 101 (2.93 ± 0.28) × 101 (−1.61 ± 0.16) × 101 −5.67 ± 0.21 (1.04 ± 0.16) × 101 1.06 ± 0.03
8 (2.3 ± 0.4) × 102 (1.12 ± 0.68) × 102 (−1.64 ± 0.29) × 101 −6.92 ± 2.91 9.45 ± 0.23 0.94 ± 0.01
9 (1.2 ± 0.1) × 103 (4.85 ± 2.50) × 102 (−1.09 ± 0.35) × 101 −2.31 ± 0.47 8.59 ± 0.31 1.17 ± 0.02